Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis


About this study

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults: 18-100
  • Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy

Exclusion Criteria:

  • Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
  • Kidney Disease/Poor Renal Function
  • Elevated creatinine levels
  • Seizures
  • Asthma
  • Hemolytic anemia
  • Claustrophobia
  • BMI over 45

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Stephen Broski, M.D.

Closed-enrolling by invitation

What is this? (?)
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Kera Delaney CCRP

(507) 422-6565


More information


Publications are currently not available

Mayo Clinic Footer